Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
22OCT

Sovereign AI Unit conflicts still unpublished

3 min read
16:30UTC

James Wise undertook in November 2025 that conflicts with his Balderton Capital role would be published on the department's website; a check of the public record on 21 September found no such publication.

TechnologyAssessed
Key takeaway

The state's equity vehicle faces no public conflicts standard of the kind now being asked of its research funder.

When his appointment as chair of the Sovereign AI Unit was announced on 21 November 2025, James Wise set out how he would handle his other job. "It will not change my role at Balderton, although any possible conflicts will be published well in advance on the Department's website," he wrote⁠1. Wise is a partner at the venture firm Balderton Capital, and has chaired the Unit since it launched on 16 April 2026. The Unit can commit up to £500 million in equity, and took a position in CuspAI in July.

That undertaking was checked at source on 21 September rather than through a search engine. The Unit's own site carries no governance material. The gov.uk organisation pages for the Department for Business and Trade, the Department for Business, Innovation, Science and Trade and the Department for Science, Innovation and Technology, including that department's own governance page, name neither the Unit nor its chair. The DSIT Annual Report and Accounts 2025-26 runs two conflicts-of-interest sections and Wise appears in neither⁠2. The Unit was delivered by a department abolished in July 2026, a machinery change this topic leaves to its own story, which may explain where such a page would now sit.

One distinction decides how much any of that weighs. Wise is not a senior civil servant and he does not sit on a departmental board, so neither of those two registers is one he was required to appear in. No rule obliged him to publish anything. He gave an undertaking, and the public record does not yet show it discharged. An undertaking outstanding and a duty breached are different things, and a reader should hold them apart.

Nothing here alleges wrongdoing by Wise or by the Sovereign AI Unit. Dame Chi Onwurah has asked government to explain the conflict-of-interest standard applied at a state research funder. Whether the same standard applies to a state investor writing equity cheques into the sector its chair invests in professionally has not been put to anyone.

Deep Analysis

In plain English

James Wise chairs the Sovereign AI Unit, a government body, while also working as a partner at Balderton Capital, a venture capital firm that invests in technology companies. Almost a year ago he promised that if his two roles ever conflicted, the details would be published on a government website well in advance. That page does not exist yet. This is not because he broke a rule: no rule required him to publish anything, because his role sits outside the normal system that makes officials declare outside interests. It means his own promise, not government policy, is the only thing making this checkable, and right now there is nothing to check.

Deep Analysis
Root Causes

James Wise is not a senior civil servant and does not sit on a departmental board, so the Cabinet Office's standard rules on registering and publishing outside interests, built for officials and board members, do not apply to his role as Sovereign AI Unit chair. No statute or code of conduct required the publication he undertook to make.

That gap is structural, not particular to this unit: government has created advisory and unit-chair roles faster than it has extended the machinery that governs conflicts of interest to cover them, leaving transparency for figures like Wise dependent on voluntary commitment rather than a rule with a compliance check behind it.

What could happen next?
  • Precedent

    If the Sovereign AI Unit eventually adopts a register of interests along the lines UKRI already publishes for its Council members, it would close the specific gap this case has exposed for future non-civil-servant unit chairs.

First Reported In

Update #15 · Nscale takes $103.4bn of contracts to NYSE

James Wise· 21 Sept 2026
Read original →
Causes and effects
This Event
Sovereign AI Unit conflicts still unpublished
The conflict-of-interest standard a select committee has asked government to explain for a state research funder has not been put to the state's equity investor.
Different Perspectives
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.
CDP Venture Capital
CDP Venture Capital
CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.
EDBI
EDBI
Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.
Forbion
Forbion
Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.
British Business Bank
British Business Bank
The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.
Stryker Corporation
Stryker Corporation
Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.